Heart Failure and Cardiac Dysfunction
Corteria Pharmaceuticals focuses on chronic heart failure and worsening heart failure, with research activity centered on symptoms, fluid balance, and cardiac structure in patients with advanced cardiovascular disease.
- Natriuresis
- N-terminal pro B-type natriuretic peptide (NT-proBNP)
- Kansas City Cardiomyopathy Questionnaire (KCCQ) symptom burden
- Left atrial volume index (LAVi)
The sponsor’s heart failure portfolio includes work in both symptomatic deterioration and broader chronic disease management, reflecting a strong therapeutic interest in cardiac remodeling and congestion-related outcomes.
Metabolic and Weight-Related Disorders
Research activity also extends to obesity and body weight regulation, including studies involving healthy participants to support evaluation of subcutaneous treatment strategies relevant to metabolic disease.
- Obesity
- Body weight change
- Subcutaneous administration
This area links metabolic outcomes with cardiology-focused development, particularly where weight control and fluid status are clinically relevant.
Healthy Volunteer and Early Clinical Evaluation
Several studies involve healthy subjects, indicating interest in early human assessment of safety, tolerability, and pharmacokinetics for new therapeutic candidates.
- Safety and tolerability
- Pharmacokinetics
- Injection strategy optimization
These activities support clinical development in both cardiometabolic and endocrine-related treatment settings.
Peptide-Based Therapeutics
The funded trials include candidates such as COR-1167 and COR-1389, pointing to a development program built around novel peptide-based or receptor-targeted therapies for cardiovascular and metabolic indications.
- Corticotrophin releasing factor 2 pathway
- Subcutaneous dosing
- Cardiometabolic therapeutics
The research portfolio is concentrated on mechanisms relevant to heart failure physiology and treatment delivery in outpatient settings.
